Exhibit 4.3

February 28, 2006

Iroquois Capital LP

641 Lexington Avenue

26^th Floor

New York, New York

USA 10022

Attention:Joshua Silverman

Dear Sirs:

Re:	Generex Biotechnology Corporation
	- Amendment to Jan 20 06 Additional Investment Right

We make reference to the additional investment right issued by Generex Biotechnology Corporation (the “Company”) to Iroquois Capital LP (“Iroquois”) on January 20, 2006 pursuant to which the Company, inter alia, granted to Iroquois the right to purchase a $1,000,000 principal amount debenture convertible at $1.25 per share (the “AIR”).

The Initial Exercise Date (as that term is defined in the AIR) of the AIR is expressed therein as the 181^st day after the date thereof. The Company hereby confirms that, in consideration of the exercise of the AIR by Iroquois and the delivery to the Company of a Notice of Exercise in respect thereof on or before the close of business on February 28, 2006, the Company has agreed to abridge the Initial Exercise Date and to honor the aforementioned Notice of Exercise.

Yours truly,

Generex Biotechnology Corporation

/s/ Mark A. Fletcher

Mark A. Fletcher

Executive Vice-President, General Counsel

maf:hs